The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study.
 
Tejas Patil
Stock and Other Ownership Interests - crispr therapeutics; Novartis; Roche/Genentech
 
Rao Rashid Mushtaq
Stock and Other Ownership Interests - Abbott Laboratories; Amazon; Amgen; Boston Scientific; Bristol-Myers Squibb; Celgene; Edwards Lifesciences; Facebook; Gilead Sciences; Johnson & Johnson; Medtronic
 
Sydney Marsh
No Relationships to Disclose
 
Christine Azelby
No Relationships to Disclose
 
Miheer Pujara
No Relationships to Disclose
 
Dara Aisner
Honoraria - AstraZeneca; Clovis Oncology
Consulting or Advisory Role - Abbvie; Bristol-Myers Squibb; Inivata
Research Funding - Genentech/Roche (Inst)
Patents, Royalties, Other Intellectual Property - Patent pending for pneumatic cell collection device
Travel, Accommodations, Expenses - SeraCare
 
William T. Purcell
No Relationships to Disclose
 
Erin Lynn Schenk
Honoraria - Takeda
Consulting or Advisory Role - Abbvie
Other Relationship - Elsevier
 
Paul A. Bunn
Consulting or Advisory Role - AstraZeneca/MedImmune; Bristol-Myers Squibb; Genentech/Roche; Lilly; Merck; Merck Serono
Research Funding - Genentech (Inst)
 
Jose Maria Pacheco
Honoraria - Takeda; Takeda
Consulting or Advisory Role - AstraZeneca; AstraZeneca; Novartis
Research Funding - Pfizer (Inst)
Travel, Accommodations, Expenses - AstraZeneca; AstraZeneca; Novartis
 
D. Ross Camidge
Honoraria - AstraZeneca; bio-thera; Daiichi Sankyo; G1 therapeutics; Genoptix; Hansoh; Ignyta; Lycera; Mersana; Revolution Medicines; Roche; takeda
Research Funding - Takeda
 
Robert Charles Doebele
Stock and Other Ownership Interests - Rain Therapeutics
Consulting or Advisory Role - AstraZeneca; Bayer; GreenPeptide; Ignyta; OncoMed; Rain Therapeutics; Roche/Genentech; Takeda
Research Funding - Ignyta (Inst)
Patents, Royalties, Other Intellectual Property - Licensing fees for biologic materials from Genentech (Inst); Licensing fees for patent from Rain Therapeutics; Licensing Fees from Abbott Molecular for Patent PCT/US2013/057495; Licensing fees from Ignyta for biologic materials (Inst)
Travel, Accommodations, Expenses - Ignyta; Rain Therapeutics; Roche/Genentech